Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent

Oncotarget

Volumn 6, Issue 6, 2015, Pages 3590-3599

  Sabbieti, Maria Giovanna ^a   Agas, Dimitrios ^a   Capitani, Melania ^a   Marchetti, Luigi ^a   Concetti, Antonio ^a   Vullo, Cecilia ^a   Catone, Giuseppe ^a   Gabai, Vladimir ^b   Shifrin, Victor ^b   Sherman, Michael Y ^c   Shneider, Alexander ^b   Venanzi, Franco M ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b Cure Lab   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic inflammation; Immunotherapy; Osteoporosis; p62 SQSTM1

Indexed keywords

CYTOKINE; DNA VACCINE; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PLASMID DNA; PROTEIN P62; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; DNA; SEQUESTOSOME 1; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SQSTM1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DENSITY; BONE MARROW STROMA CELL; BONE MINERAL; CONTROLLED STUDY; DOWN REGULATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; TREATMENT DURATION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MOLECULAR CLONING; PHARMACOLOGY; PLASMID; RANDOMIZATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTI-INFLAMMATORY AGENTS; CLONING, MOLECULAR; DNA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; PLASMIDS; RANDOM ALLOCATION; SEQUESTOSOME-1 PROTEIN; VACCINES, DNA;

EID: 84924239940     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2884     Document Type: Article

References (33)

1. Moscat J, Diaz-Meco MT. p62: a versatile multitasker takes on cancer. Trends Biochem. Scie. 2012; 37:230-236.
2. Geetha T, Vishwaprakash N, Sycheva M, Babu JR. Sequestosome 1/p62: across diseases. Biomarkers. 2012; 17:99-103.
3. Park S, Ha S-D, Coleman M, Meshkibaf S, Kim SO. p62/SQSTM1 Enhances NOD2-mediated signaling and cytokine production through stabilizing NOD2 oligomerization. PLoS ONE. 2013; 8:1-11.
4. Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging. 2012; 4:166-175.
5. Yu HB, Kielczewska A, Rozek A, Takenaka S, Li Y, Thorson L, Hancock RE, Guarna MM, North JR, Foster LJ, Donini O, Finlay BB. Sequestosome-1/p62 is the key intracellular target of innate defense regulator peptide. J. Biol. Chem. 2009; 284:36007-36011.
6. Venanzi F, Shifrin V, Sherman M, Gabai V, Kiselev O, Komissarov A, Grudinin M, Shartukova M, Romanovskaya-Romanko EA, Kudryavets Y, Bezdenezhnykh N, Lykhova O, Semesyuk N, Concetti A, Tsyb A, Filimonova M, Makarchuk V, Yakubovsky R, Chursov A, Shcherbinina V, Shneider A. Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector. Oncotarget. 2013; 4:1829-1835.
7. Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chursov A, Latanova A, Shcherbinina V, Shifrin V, Shneider A. Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget. 2014; 25[Epub ahead of print].
8. Yip KHM, Feng H, Pavlos NJ, Zheng MH, Xu J. p62 Ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-B ligand-induced osteoclast formation a new insight into the pathogenesis of Paget's disease of bone. Amer. J. Pathology. 2006; 169:503-514.
9. Rea SL, Walsh JP, Ward L, Yip K, Ward BK, Kent GN, Steer JH, Xu J, Ratajczak T. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-B signaling and Paget's disease of bone with severe phenotype. J. Bone Miner. Res. 2006; 21:1136-1145.
10. Najat DE, Thomas T, Hagen T, Shaw B, Sheppard PW, Falchetti A, Marini F, Brandi ML, Long JE, Cavey JR, Searle MS, Layfield R. Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone J. Bone Min. Res. 2009; 24:632-642.
11. Kim JY, Ozato K. The Sequestosome 1/p62 Attenuates Cytokine Gene Expression in Activated Macrophagesby Inhibiting IFN Regulatory Factor 8 and TNF Receptor-Associated Factor 6/NF-kB. J. Immunol. 2009; 182: 2131-2140.
12. Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, Duran A, Castilla EA, Metallo CM, Diaz-Meco MT, Moscat J. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell. 2014; 26:121-135.
13. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. NY. Acad. Sci. 2000; 908:244-254.
14. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 2002; 23:279-302.
15. Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J. Clin. Immunol. 2009; 29:555-67.
16. Pacifici R. Role of T Cells in Ovariectomy Induced Bone Loss-Revisited. J. Bone Min. Res. 2012; 27:231-239.
17. Duran A, Serrano M, Leitges M, Flores JM, Picard S, Brown JP, Moscat J, Diaz-Meco MT. The atypical PKC-interacting protein p62 is an important mediator of RANK activated osteoclastogenesis. Dev. Cell. 2004; 6:303-309.
18. Abu-Taha M1, Rius C, Hermenegildo C, Noguera I, Cerda-Nicolas JM, Issekutz AC, Jose PJ, Cortijo J, Morcillo EJ, Sanz MJ. Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol. 2009; 183:1393-402.
19. Baeza I, De Castro NM, Giménez-Llort L, De la Fuente M. Ovariectomy, a model of menopause in rodents, causes a premature aging of the nervous and immune systems. J. Neuroimmunol. 2010; 219:90-99.
20. Jee WSS, Yao W. Overview: animal models of osteopenia and osteoporosis. Musculoskel. Neuron. Interact. 2001; 1:193-207.
21. Goswami J, Hernández-Santos N, Zuniga LA, Gaffen SL. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur. J. Immunol. 2009; 39:2831-2839.
22. Sabbieti MG, Agas D, Marchetti L, Coffin JD, Xiao L, Hurley MM. BMP-2 differentially modulates FGF-2 isoform effects in osteoblasts from newborn transgenic mice. Endocrinology. 2013; 154:2723-33.
23. Yu M, Qi X, Moreno JL, Farber DL, Keegan AD. NF-κB signaling participates in both RANKL-and IL-4-induced macrophage fusion: receptor cross talk leads to alterations in NF-κB pathways. J. Immunol. 2011; 187:1797-806.
24. Seibenhener ML, Zhao T, Du Y, Calderilla-Barbosa L, Yan J, Jiang J, Wooten MW, Wooten MC. Behavioral effects of SQSTM1/p62 overexpression in mice: support for a mitochondrial role in depression and anxiety. Behav Brain Res. 2013; 248:94-103.
25. Nishikawa K, Nakashima T, Takeda S, Isogai M, Hamada M, Kimura A, Kodama T, Yamaguchi A, Owen MJ, Takahashi S, Takayanagi H. Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J. Clin. Invest. 2010; 120:3455-65.
26. Gabai VL, Shifrin VI. Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int. Rev. Immunol. 2014; 33:375-82.
27. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ Cummings SR; CORE Investigators . Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst. 2004; 96:1751-61.
28. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 2006; 355:125-37.
29. Lippuner K. The future of osteoporosis treatment-a research update. Swiss Med Wkly. 2012; 142:w13624.
30. Sabbieti MG, Agas D, Marchetti L, Santoni G, Amantini C, Xiao L, Menghi G, Hurley MM. Signaling pathways implicated in PGF2α effects on Fgf 2+/+ and Fgf 2-/-osteoblasts J. Cell. Physiol. 2010; 224:465-474.
31. Lopez Franco GE, Tyriina TK, Litscher SJ, Urban-Piette M, Robert D, Blank RD. Accuracy and Precision of PIXImus Densitometry for Ex Vivo Mouse Long Bones. J. Clin. Dens. 2004; 7:326-333.
32. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J. Clin. Invest. 2000; 105:1085-1093.
33. Agas D, Sabbieti MG, Marchetti L, Xiao L, Hurley MM. FGF-2 enhances Runx-2/Smads nuclear localization in BMP-2 canonical signaling in osteoblasts. J. Cell. Physiol. 2013; 228:2149-2158.